CAS 1306760-87-1: Ozanimod
Description:Ozanimod is a selective sphingosine 1-phosphate receptor modulator, primarily targeting S1P receptors 1 and 5. It is utilized in the treatment of certain autoimmune conditions, notably multiple sclerosis and ulcerative colitis. The compound exhibits a unique mechanism of action by modulating lymphocyte trafficking, effectively reducing the number of circulating lymphocytes and thereby mitigating inflammatory responses. Ozanimod is characterized by its oral bioavailability and a relatively long half-life, allowing for once-daily dosing. Its chemical structure includes a bicyclic core, contributing to its specificity and potency. The substance has undergone extensive clinical trials, demonstrating efficacy in reducing disease activity and improving patient outcomes. As with many pharmacological agents, potential side effects may include infections, liver enzyme elevations, and cardiovascular effects, necessitating careful monitoring during treatment. Overall, Ozanimod represents a significant advancement in the therapeutic landscape for managing chronic inflammatory diseases.
Formula:C23H24N4O3
InChI:InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
InChI key:InChIKey=XRVDGNKRPOAQTN-FQEVSTJZSA-N
SMILES:N#CC=1C=C(C=CC1OC(C)C)C2=NC(=NO2)C=3C=CC=C4C3CCC4NCCO
- Synonyms:
- Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-
- Ozanimod
- 5-[3-[1-(S)-(2-Hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-isopropoxybenzonitrile
- 5-[3-[(1S)-2,3-Dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
- RPC 1063